Ensysce Biosciences Announces Upcoming Conference and Industry Event Participation
ACCESS Newswire (Wed, 2-Sep 8:31 AM ET)
Ensysce Biosciences Completes Final Phase of PF614-MPAR-102 Clinical Study
ACCESS Newswire (Mon, 31-Aug 8:30 AM ET)
Ensysce Biosciences to Showcase "A New Era in Pain Therapeutics" at PAINWeek 2026 Symposium
ACCESS Newswire (Thu, 20-Aug 8:00 AM ET)
Ensysce Biosciences Reports Second Quarter 2026 Financial Results and Recent Business Highlights
ACCESS Newswire (Thu, 13-Aug 4:15 PM ET)
Why Investors Are Watching These Healthcare Movers
Globe Newswire (Thu, 6-Aug 12:31 PM ET)
ENSC’s $77 Million Financing and Cy Biopharma Acquisition Puts Phase 2 Pain Therapy on Fast Track
Market Chameleon (Thu, 6-Aug 6:28 AM ET)
Ensysce Biosciences Announces Acquisition of Cy Biopharma and up to $77 Million Private Financing
ACCESS Newswire (Thu, 6-Aug 8:00 AM ET)
ACCESS Newswire (Tue, 14-Jul 8:00 AM ET)
Ensysce Biosciences Enrolls First Patient in Final Phase of PF614-MPAR-102 Clinical Study
ACCESS Newswire (Fri, 26-Jun 8:00 AM ET)
Ensysce Biosciences Targets Regulatory Risk With Strategic AMA Session as PF614 Program Gains Focus
Market Chameleon (Thu, 5-Mar 6:08 AM ET)
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.
Ensysce Biosciences trades on the NASDAQ stock market under the symbol ENSC.
As of September 11, 2026, ENSC stock price declined to $0.49 with 504,155 million shares trading.
ENSC has a beta of 2.60, meaning it tends to be more sensitive to market movements. ENSC has a correlation of 0.06 to the broad based SPY ETF.
ENSC has a market cap of $9.47 million. This is considered a Sub-Micro Cap stock.
Last quarter Ensysce Biosciences reported $1 million in Revenue and -$.20 earnings per share. This beat revenue expectation by $170,000 and exceeded earnings estimates by $.30.
In the last 3 years, ENSC traded as high as $30.90 and as low as $.23.
The top ETF exchange traded funds that ENSC belongs to (by Net Assets): VXF.
ENSC has underperformed the market in the last year with a return of -77.1%, while SPY returned +17.4%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in ENSC shares. However, ENSC has outperformed the market in the last 3 month and 2 week periods, returning +84.8% and +21.8%, while SPY returned +3.9% and -0.7%, respectively. This indicates ENSC has been having a stronger performance recently.
ENSC support price is $.47 and resistance is $.56 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ENSC shares will trade within this expected range on the day.
